Definium Therapeutics says synthetic LSD trial shows positive anxiety results; shares jump as stock is up 190% in 2026

Definium Therapeutics reported positive results for synthetic LSD in reducing anxiety symptoms, triggering another sharp share move after a 190% year-to-date run. The update reinforces risk appetite in early-stage biotech and highlights continued investor willingness to re-rate clinical-stage names on trial readouts. Near-term impact should be concentrated in single-name biotech volatility rather than broader macro or crypto markets.